Preveen Ramamoorthy,
Assistant Professor/Director,
National Jewish Health
Dr. Preveen Ramamoorthy founded the Molecular Diagnostics department at National Jewish Health, Denver in 2007. Currently, he directs the translation of biomarkers into molecular diagnostic tests at the Advanced Diagnostic Laboratories at National Jewish Health. Dr. Ramamoorthy’s laboratory develops genome based diagnostic tests for rapid diagnosis of infectious diseases, diagnosis of genetic disorders, disease prognosis and companion diagnostics and integrating them into personalized medicine clinical programs at National Jewish Health. , Prior to joining National Jewish Health Dr. Ramamoorthy was involved in the development of viral vaccines, cancer vaccines and monoclonal antibodies at MedImmune (Astra Zeneca company). Dr. Ramamoorthy completed his post-doctoral fellowship at Walter Reed Army Institute of Research, Silver Spring in genomics and molecular diagnostics. During his Ph.D at Clemson University Dr. Ramamoorthy co-invented a prolactin receptor antagonist, a molecular therapeutic drug for breast cancer. Dr. Ramamoorthy obtained his Master’s in Medical Microbiology at the University of Madras before he embarked upon his Ph.D program at Clemson University . Dr. Ramamoorthy co-founded the Q-PCR symposium USA in 2007. He. serves on the scientific advisory board of PrognosDx, TATAA Biocenter, Global Chest Initiatives and International Asthma Services. He has numerous publications in internationally reputed journals and his work was recently featured in Nature Biotechnology (July 2011 publication).
|
|
|